Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541706 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3260470 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1246192 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL26978842 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1049466 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22836423 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17981462 | 1.00 | MAPT (0.57) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5153957 | 0.98 | TSHR (0.58) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1444871 | 0.91 | — | — | |
| SCHEMBL18102172 | 0.89 | ALDH1A1 (0.54) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479812-B2 | Fatty acid derivatives and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2024027706-A1 | BCL-XL DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-11555021-B2 | Fatty acid derivatives and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-01-17 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-11510888-B2 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-RE49238-E1 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| EP-3649115-A1 | FATTY ACID DERIVATIVES AND THEIR USE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019010414-A1 | FATTY ACID DERIVATIVES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-01-10 | — | — | WO | disclosed |
| US-9248145-B2 | Two alkylresorcinol synthase genes from sorghum; cloning, expression, transformation and characterization | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2016-02-02 | — | — | US | disclosed |
| CN-103664604-B | Bromo-9,11,19-tri-alkynes-17, the 21-diene behenic acid Lipase absobed methods of bromination yne compounds E, E-22- | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-04 | — | — | CN | disclosed |
| CN-103664604-A | Synthesis method of brominated eneyne compound E,E-22-bromo-9,11,19-trialkynyl-17,21-diene behenate | SHANGHAI INST MATERIA MEDICA | 2014-03-26 | — | — | CN | disclosed |
| US-20110225676-A1 | Two Novel Alkylresorcinol Synthase Genes from Sorghum; Cloning, Expression, Transformation and Characterization | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2011-09-15 | — | — | US | disclosed |
| US-20090317660-A1 | Methods of Dispersing Carbon Nanotubes | BATTELLE MEMORIAL INSTITUTE | 2009-12-24 | — | — | US | disclosed |
| US-20090317660-A1 | Methods of Dispersing Carbon Nanotubes | BATTELLE MEMORIAL INSTITUTE | 2009-12-24 | — | — | US | disclosed |
| WO-2008054472-A9 | METHODS OF DISPERSING CARBON NANOTUBES | BATTELLE MEMORIAL INSTITUTE (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008054472-A2 | METHODS OF DISPERSING CARBON NANOTUBES | BATTELLE MEMORIAL INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | MAPT 115/4885CYP1A2 4231/4885CYP2D6 4534/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | MAPT 4766/4885CYP1A2 187/4885CYP2D6 391/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | MAPT 875/4885CYP1A2 2855/4885CYP2D6 3218/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | MAPT 4766/4885CYP1A2 187/4885CYP2D6 391/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | MAPT 115/4885CYP1A2 4231/4885CYP2D6 4534/4885 |
| US-12479812-B2 | Fatty acid derivatives and their use | FFAR3, FFAR1, FFAR2 | MAPT 193/4885CYP1A2 1129/4885CYP2D6 1144/4885 |
| US-11555021-B2 | Fatty acid derivatives and their use | FFAR3, FFAR1, FFAR2 | MAPT 193/4885CYP1A2 1129/4885CYP2D6 1144/4885 |
| US-11510888-B2 | Alleviating oxidative stress disorders with PUFA derivatives | GPX4, ALOX12, ALOX15 | MAPT 945/4885CYP1A2 2113/4885CYP2D6 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.